Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| CYTOKINETICS | 6 | 1 | -0,93 % | ||
| AMGEN | 5 | 27 | +0,59 % | ||
| DISC MEDICINE | 5 | 7 | -11,50 % | ||
| GILEAD SCIENCES | 5 | 5 | +0,83 % | ||
| BIONTECH | 4 | 13 | -0,06 % | ||
| BIOMARIN PHARMACEUTICAL | 4 | 12 | +0,46 % | ||
| SAREPTA THERAPEUTICS | 2 | 1 | -0,42 % | ||
| ALTIMMUNE | 2 | - | +0,91 % | ||
| RHYTHM PHARMACEUTICALS | 1 | 3 | -1,04 % | ||
| TERNS PHARMACEUTICALS | 1 | 2 | +0,58 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:30 | Biontech-Aktie überrascht Experten: Strategen sehen erhöhte Spannung - nicht verpassen! | Hebelschein-Spekulant | |||
| 15:26 | Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger | 4 | Insider Monkey | ||
| 15:26 | BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus | 3 | Insider Monkey | ||
| 09:50 | Samstag Meldung zu BIONTECH SE ADR: Jetzt wird's ernst! | 38 | Maximilian Berger | ||
| 08:06 | Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal | 12 | Benzinga.com | ||
| 06:10 | Cathie Woods ARK Invest setzt Verkäufe bei Ionis Pharma fort | 5 | Investing.com Deutsch | ||
| 03:29 | FDA Approves Cytokinetics' MYQORZO For Treatment Of Obstructive Hypertrophic Cardiomyopathy | 17 | RTTNews | ||
| Fr | Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy | 15 | Seeking Alpha | ||
| Fr | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 11 | GlobeNewswire (USA) | ||
| Fr | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | 1 | Investing.com | ||
| Fr | Sarepta Therapeutics tauscht Wandelanleihen im Wert von 291,4 Mio. USD um | 9 | Investing.com Deutsch | ||
| Fr | Stifel bestätigt "Buy"-Rating für Disc Medicine trotz Spekulationen um FDA-Prüfung | 1 | Investing.com Deutsch | ||
| Fr | Jefferies reiterates Buy rating on Disc Medicine stock amid FDA concerns | 2 | Investing.com | ||
| Fr | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 8 | GlobeNewswire (USA) | ||
| Fr | FDA-Zulassung für Herzmedikament MYQORZO beflügelt Cytokinetics-Aktie | 18 | Investing.com Deutsch | ||
| Fr | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | 1.179 | dpa-AFX | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| Fr | Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders | 1 | Insider Monkey | ||
| Fr | Trump Announces Reduced Drug Pricing Deal With Amgen, Gilead And Other Pharma Firms | 21 | Forbes | ||
| Fr | BioMarin Stock Surges Nearly 20% After $4.8 Bln Amicus Acquisition News | 304 | AFX News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) shares rose 19.51%, climbing $10.13 to $62.08, after the company announced a definitive agreement to acquire Amicus Therapeutics for... ► Artikel lesen | |
| Fr | Cytokinetics, Incorporated: Cytokinetics Announces FDA Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms | 2.161 | GlobeNewswire (Europe) | MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approved... ► Artikel lesen |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .